Mon panier

Cynomolgus / Rhesus macaque B7-1 / CD80 Protein, Fc Tag (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CD0-C5252-100ug
$295.00
CD0-C5252-1mg (500ug X 2)
$2000.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    CD80, B7, B7-1, B7.1, BB1, CD28LG, CD28LG1, LAB7

  • Source

    Cynomolgus / Rhesus macaque B7-1, Fc Tag (CD0-C5252) is expressed from human 293 cells (HEK293). It contains AA Val 35 - Asn 242 (Accession # G7NXN7). In the region Val 35 - Asn 242, the amino acid sequences of Cynomolgus and Rhesus macaque B7-1 are identical.

    Predicted N-terminus: Val 35

    Request for sequence
  • Molecular Characterization

    B7-1 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 50.5 kDa. The protein migrates as 60-90 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    B7-1 SDS-PAGE

    Cynomolgus / Rhesus macaque B7-1, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    B7-1 SEC-MALS

    The purity of Cynomolgus / Rhesus macaque B7-1, Fc Tag (Cat. No. CD0-C5252) is more than 95% and the molecular weight of this protein is around 115-145 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     B7-1 ELISA

    Immobilized Cynomolgus / Rhesus macaque CTLA-4, His Tag (Cat. No. CT4-C5227) at 2 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque B7-1, Fc Tag (Cat. No. CD0-C5252) with a linear range of 1-8 ng/mL (QC tested).

    Protocol
  • Bioactivity-BLI

     B7-1 BLI

    Loaded Cynomolgus / Rhesus macaque B7-1, Fc Tag (Cat. No. CD0-C5252) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag with an affinity constant of 4.5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response.
B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Cluster of differentiation 80

  • Catégorie:

  • Nombre de médicaments répertoriés:

    2 Détails

  • Nombre de médicaments cliniques:

    10 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte